Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
ELEV Price/Volume Stats
| Current price | $0.58 | 52-week high | $5.83 |
| Prev. close | $0.63 | 52-week low | $0.44 |
| Day low | $0.55 | Volume | 2,504,300 |
| Day high | $0.66 | Avg. volume | 1,482,442 |
| 50-day MA | $0.60 | Dividend yield | N/A |
| 200-day MA | $2.17 | Market Cap | 34.29M |
ELEV Stock Price Chart Interactive Chart >
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
ELEV Price Returns
| 1-mo | -4.16% |
| 3-mo | -1.01% |
| 6-mo | -76.33% |
| 1-year | 23.40% |
| 3-year | -88.16% |
| 5-year | N/A |
| YTD | 8.01% |
| 2023 | -43.47% |
| 2022 | -84.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...